$0.91+8.5%Nov 13 close
Reported results on November 13, 2026; they are not in these figures yet.
Figures through June 30, 2026, from the 10-Q filed August 14, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$14.8M | -$6.2M | -138.27% |
| Profit per share | -$0.40 | -$0.32 | -25.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Annovis Bio, Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“The third quarter marked a shift in our focus from enrolling patients in DUET-AD to executing the trial and preparing for the first data readout and for filing a New Drug Application (NDA),”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Annovis Bio, Inc.’s Item 2.02 8-K filed November 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.